Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan 2;4(1):e003698.
doi: 10.1136/bmjopen-2013-003698.

Multidrug and optimal heart failure therapy prescribing in older general practice populations: a clinical data linkage study

Claire A Rushton  1 , Anna Strömberg, Tiny Jaarsma, Umesh T Kadam
Affiliations

Multidrug and optimal heart failure therapy prescribing in older general practice populations: a clinical data linkage study

Claire A Rushton et al. BMJ Open. .

Abstract

Objective: To investigate multidrug therapy in the cardiovascular disease (CVD) population and whether it was associated with suboptimal drug prescribing in heart failure (HF).

Design: A population-based cross-sectional clinical data linkage study.

Setting: The clinical database populations were registered with three general practices in North Staffordshire that are part of a research network.

Participants: 3155 patients aged 50 years and over were selected on the basis of a CVD-related prescription and a CVD consultation code applied to their electronic medical record in a 2-year time period. All available diagnostic data were linked to all drugs prescribed data during this time period. Two study groups were: (1) HF and (2) non-HF CVD (reference group).

Exposure: A standard drug formulary system was used to define four multidrug count categories based on the number of different British National Formulary drug chapters prescribed at the same time.

Primary and secondary outcome measures: Optimal HF therapy was defined as the prescribing of ACE inhibitor (ACEi) or a combination of ACEi and β-blocker in the 2-year time window. An additional three specific CVD drug categories that are indicated in HF were also measured.

Results: The HF group, compared with the reference group, had higher non-CVD multidrug therapy (26% with 7 or more counts compared with 14% in the non-HF CVD reference group). For the first-choice optimal drug treatment for HF with ACEi (64%) or ACEi and β-blocker combined therapy (23%), the multidrug-adjusted associations between the HF group and the reference group were OR 3.89; 95% CI 2.8 to 5.5 and 1.99; 1.4 to 2.9, respectively. These estimates were not influenced by adjustment for sociodemographic factors and multidrug counts.

Conclusions: Multidrug therapy prescribing is much higher in the HF group than in a comparable CVD group but did not influence optimal drug prescribing.

Keywords: Comorbidity; Heart Failure; Polypharmacy; Prescriptions.

PubMed Disclaimer

References

    1. Thomas S, Rich M. Epidemiology, pathophysiology, and prognosis of heart failure in the elderly. Clin Geriatr Med 2007;23:1–10 - PubMed
    1. Lindenfeld J, Albert N, Boehmer J, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 2010;16:e1–194 - PubMed
    1. NICE Chronic heart failure: National Clinical Guideline for diagnosis and management in primary and secondary care. London: Royal College of Physicians, 2010 - PubMed
    1. Stewart S, Jenkins A, Buchanc S, et al. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 2002;4:361–71 - PubMed
    1. The NHS Information Centre The national heart failure audit. Leeds: NHS, Information Centre for Health and Social Care, 2010

Publication types